Rapport Therapeutics, Inc.
RAPP
$14.77
-$0.16-1.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -47.52% | -6.15% | -47.79% | -101.37% | -182.65% |
| Total Depreciation and Amortization | 21.15% | 60.53% | 390.57% | 852.17% | 890.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 183.85% | -50.18% | 237.60% | 41.10% | 78.20% |
| Change in Net Operating Assets | -2,639.84% | 86.28% | -31.02% | -120.88% | 89.34% |
| Cash from Operations | -53.31% | -14.89% | -39.48% | -202.64% | -147.80% |
| Capital Expenditure | 97.72% | 72.85% | 84.27% | -169.23% | -1,024.42% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 121.31% | 152.19% | 141.64% | -- | -- |
| Cash from Investing | 121.10% | 150.16% | 140.59% | -101,901.92% | -124,439.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -- | -- | 530,230.00% |
| Repurchase of Common Stock | -- | -- | -- | -34,750.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | 63.75% |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -122.26% | -- | -- | -- | 807.50% |
| Cash from Financing | -100.04% | -99.99% | 105.00% | -101.63% | 177,158.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -107.07% | -80.60% | 119.62% | -188.69% | 629.85% |